Biogen (NASDAQ:BIIB) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co.
Biogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by equities researchers at JPMorgan Chase & Co. from $185.00 to $175.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside […]
Biogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by equities researchers at JPMorgan Chase & Co. from $185.00 to $175.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside […]
